Skip to content

Information about how we use cookies

This website uses cookies to provide you with the best possible experience of the website. By continuing to use the website, you agree to our use of cookies. More information about our privacy policy and how we handle cookies can be found here

Help links

  • Sitemap
  • Choose country
    • Swedish
    • Norwegian
    • Danish
    • Finnish
    • Dutch
Navamedic Navamedic

Main navigation

  • Portfolio
  • Investor relations
  • Newsroom
  • About Navamedic
  • Contact
Search

Newsroom

  • 2019
  • 2018
  • 2017
  • 2016
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January

October

  • 2016-10-28

    Navamedic: Launches treatment device for refractory depression

    Oslo, 28 October 2016 – Navamedic ASA (OSE: NAVA), today announced an exclusive agreement with the Danish company, Re5 ApS, for Nordic distribution of Re5-NTS®, an innovative, non-invasive treatment device based on patented Danish technology, for patients with refractory depression.

Top

Navamedic ASA

Fornebuveien 42-44 P.O. Box 107 N-1325 Lysaker Norway

Privacy Policy

Investor relations

  • The Share
  • Annual Reports
  • Quarterly Reports
  • IFRS
  • Presentations
  • Corporate Governance
  • Financial Calendar
  • IR Contacts
  • Product Launches

About Navamedic

  • Management
  • Board of Directors
  • Company History
  • Careers
  • Our Partners
  • Business Development
  • Privacy Policy

Copyright © 2016 Navamedic ASA Sitemap Contact

  • Facebook